ReCode Therapeutics
Optimized mRNA and gene correction medicines with targeted organ/tissue delivery platform
- Sector
- Biotech
- Headquarters
- Menlo Park, CA
- Founded
- 2015
- Latest Form D
- $29.4M, Oct 2025
- Total capital
- $97.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $97.4M
- 4 Form D · last Oct 2025
- 12 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2024
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$29.4M
- Private capital raisedForm D · SEC · 3rd filing$40M
- Private capital raisedForm D · SEC · 2nd filing$27.5M
- Private capital raisedForm D · SEC · 1st filing$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan S. ColowickDirectorNamed in SEC Form D filings
- Arthur E JohnsonExecutive Officer, DirectorNamed in SEC Form D filings
- Basheer S. ZadaDirectorNamed in SEC Form D filings
- David S. LockhartExecutive OfficerNamed in SEC Form D filings
- Dean S. MitchellDirectorNamed in SEC Form D filings
- Edward J HurwitzDirectorNamed in SEC Form D filings
Show all 19 people
- Helen S. KimDirectorNamed in SEC Form D filings
- Inai S. ParkDirectorNamed in SEC Form D filings
- Julia S. EastlandExecutive OfficerNamed in SEC Form D filings
- Kouki S. HarasakiDirectorNamed in SEC Form D filings
- Michael J TorresDirectorNamed in SEC Form D filings
- Oleg S. NodelmanDirectorNamed in SEC Form D filings
- Patricia S. MillicanDirectorNamed in SEC Form D filings
- Peter A. ThompsonDirectorNamed in SEC Form D filings
- Rakhshita S. DharDirectorNamed in SEC Form D filings
- Rana S. Al-HallaqDirectorNamed in SEC Form D filings
- RA S. Session IIDirectorNamed in SEC Form D filings
- Shehnaaz SulimanExecutive Officer, DirectorNamed in SEC Form D filings
- Trisha S. MillicanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingLipid Nanoparticle Compositions And Uses ThereofUSPTOApplication 19400701
- GrantedLipid Nanoparticle Compositions And Uses ThereofUSPTOUS 12,582,611
- GrantedMethod For Quantifying An Amount Of Capped Messenger RnaUSPTOUS 12,553,042
Show all 40 patent records
- Lipid Nanoparticle Compositions And Uses ThereofJul 16, 2026 · Application 19400701Pending
- Lipid Nanoparticle Compositions And Uses ThereofMar 24, 2026 · US 12,582,611Granted
- Method For Quantifying An Amount Of Capped Messenger RnaFeb 17, 2026 · US 12,553,042Granted
- Lipid Nanoparticle Compositions And Uses ThereofSep 18, 2025 · Application 19182477Pending
- Compositions, Methods And Uses For Treating Cystic Fibrosis And Related DisordersSep 11, 2025 · Application 18553975Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 4, 2025 · Application 19006037Pending
- Lipid Nanoparticle Compositions And Uses ThereofJul 22, 2025 · US 12,364,773Granted
- Lipid Nanoparticle Compositions And Uses ThereofJun 24, 2025 · US 12,337,068Granted
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofApr 10, 2025 · Application 18283143Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofMar 25, 2025 · US 12,257,318Granted
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofJan 16, 2025 · Application 18283523Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofDec 5, 2024 · Application 18282699Pending
- Compositions And Methods For Targeted Delivery To CellsNov 28, 2024 · Application 18797360Pending
- Compositions And Methods For Targeted Delivery To CellsNov 28, 2024 · Application 18780382Pending
- Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778717Pending
- Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778746Pending
- Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778439Pending
- Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778429Pending
- Lipid Nanoparticle Compositions And Uses ThereofNov 5, 2024 · US 12,133,923Granted
- Compositions And Methods For Targeted Delivery To CellsOct 22, 2024 · US 12,121,610Granted
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 19, 2024 · Application 18532995Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 12, 2024 · Application 18596141Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofAug 22, 2024 · Application 18596151Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofAug 8, 2024 · Application 18596148Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofJul 25, 2024 · Application 18420141Pending
- Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofApr 18, 2024 · Application 18282181Pending
- Compositions And Methods For Targeted Delivery To CellsOct 26, 2023 · Application 18312305Pending
- Compositions And Methods For Targeted Delivery To CellsSep 21, 2023 · Application 18311274Pending
- Lipid Nanoparticle Compositions And Uses ThereofApplication 63725936Pending
- Lipid Nanoparticle Compositions And Uses ThereofApplication PCTUS2024057850Pending
- Systems And Methods For Generating Lipid NanoparticlesApplication PCTUS2025016069Pending
- Lipid Nanoparticles For Hepatic DeliveryApplication 63647251Pending
- Lipid Nanoparticle Compositions And Uses Thereof And Method For Quantifying An Amount Of Capped Messenger RnaApplication PCTUS2024057849Pending
- Lipid Nanoparticles For Extrahepatic DeliveryApplication 63647166Pending
- Lipid Nanoparticles For Extrahepatic DeliveryApplication 63659796Pending
- Lipid Nanoparticle Compositions And Uses ThereofApplication PCTUS2024057852Pending
- Lipid Nanoparticles For Extrahepatic DeliveryApplication PCTUS2025028959Pending
- Lipid Nanoparticles For Hepatic DeliveryApplication 63737003Pending
- Lipid Nanoparticle Compositions And Uses ThereofApplication 63605392Pending
- Systems And Methods For Generating Lipid NanoparticlesApplication 63737069Pending
Related companies, and why
- RallybioSimilar federal contract value in Biotech · null in contracts
- Autobahn TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Amicus TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NuPeak Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- D3 BioSimilar federal contract value in Biotech · null in contracts
- HOLOCLARA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .